Adagio Therapeutics, Inc. – Trademark Portfolio
Entity Type: 03
Adagio Therapeutics, Inc. holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 8 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include INVIVYD. The owner is based in Waltham, MA.
1601 Trapelo Road, Suite 178
Waltham, MA 02451
Showing of trademarks Trademarks
Trademark Classifications
Adagio Therapeutics, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Legal services; security services for the protection of property and individuals
Frequently Asked Questions
How many trademarks does Adagio Therapeutics, Inc. have?
Adagio Therapeutics, Inc. has 10 U.S. trademarks filed with the USPTO. Of these, 4 registered, 6 abandoned.
What trademark classes does Adagio Therapeutics, Inc. file in?
Adagio Therapeutics, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Adagio Therapeutics, Inc.'s most well-known trademarks?
Adagio Therapeutics, Inc.'s registered trademark portfolio includes well-known marks such as INVIVYD. These are among 4 currently registered trademarks in the portfolio.
What is Adagio Therapeutics, Inc.'s trademark registration success rate?
Adagio Therapeutics, Inc. has a 40% trademark registration rate, with 4 out of 10 resolved applications resulting in successful registration. Currently, 0 applications are pending review.